Should sulfasalazine be withheld during acute illness (e.g., fever, infection, vomiting, or diarrhoea)?

Should Sulfasalazine Be Withheld While Unwell?

Yes, sulfasalazine should be temporarily withheld during active infection (fever, infection, vomiting, or diarrhea), but can generally be continued after exposure to infection without active symptoms.

Key Recommendation

The American College of Rheumatology guidance explicitly recommends temporarily withholding sulfasalazine in the setting of active infection 1. This recommendation is based on several critical concerns:

• Adverse effects of sulfasalazine can mimic or mask infection symptoms, including gastrointestinal upset, diarrhea, hepatitis, cytopenias, and rarely pneumonitis, which could be confused with signs of active infection 1
• These adverse effects could be detrimental during active illness and complicate clinical assessment
• Temporarily withholding sulfasalazine is unlikely to result in significant rheumatic disease flares 1

When to Continue vs. Withhold

Continue Sulfasalazine:

• After infection exposure but without active symptoms - The ACR guidance specifically states that sulfasalazine can be continued post-exposure (unlike some other DMARDs where there is uncertainty) 1
• When patient is well - The infection risk with sulfasalazine monotherapy is relatively small 1

Withhold Sulfasalazine:

• Active infection with fever
• Active gastrointestinal symptoms (vomiting, diarrhea) - particularly important since sulfasalazine itself causes GI side effects in 11-40% of patients 2
• Any signs of serious infection including sepsis or pneumonia 3

Critical Warning Signs Requiring Immediate Discontinuation

The FDA label emphasizes that certain symptoms mandate stopping sulfasalazine while awaiting diagnostic workup 3:

• Sore throat, fever, pallor, purpura, or jaundice - may indicate serious blood disorders or hepatotoxicity
• New or worsening infection - perform prompt diagnostic workup for infection and myelosuppression 3
• Skin rash or mucosal lesions - may indicate severe hypersensitivity reactions 3

Important Caveats

Timing matters for adverse effects: Most serious idiosyncratic reactions to sulfasalazine occur within the first 2 months of therapy 4. Agranulocytosis appears almost invariably during this period, requiring heightened vigilance for unexplained fever or nonspecific illness 4.

The drug has a good overall safety record when used appropriately, with most common side effects (GI reactions, headache) manageable by dosage adjustment 5. However, serious infections including fatal sepsis and pneumonia have been reported, sometimes associated with myelosuppression 3.

Gastrointestinal symptoms are particularly problematic because sulfasalazine commonly causes nausea, abdominal pain, and diarrhea 2, making it difficult to distinguish drug side effects from infectious gastroenteritis. This diagnostic confusion is a primary reason for withholding during active GI illness 1.

Practical Algorithm

1. Patient develops fever or infection symptoms → Withhold sulfasalazine immediately
2. Check complete blood count and urinalysis to rule out blood dyscrasias 3
3. Evaluate and treat the infection
4. Resume sulfasalazine once infection has resolved and patient is clinically stable
5. If within first 2 months of therapy, maintain higher suspicion for drug-related complications 4